Maravai LifeSciences (NASDAQ:MRVI) Sees Strong Trading Volume - Time to Buy?

Key Points

• Trading volume rose about 15% to 1,634,405 shares with the stock last at $3.2230, trading near its 50‑day ($3.17) and 200‑day ($3.34) moving averages and a market cap of roughly $847M.
• Analyst backdrop: upgrades include Wall Street Zen moving to "hold" and Wells Fargo raising its target to $4.50 (overweight), while the consensus rating is "Hold" with an average price target of $5.38 (three Buys, one Hold, one Sell).
• Earnings beat quarterly estimates (EPS -$0.04 vs. -$0.07; revenue $49.87M vs. $49.06M) but the company remains unprofitable with a -70.4% net margin and negative ROE, and analysts forecast FY EPS of -$0.24.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) shares saw an uptick in trading volume on Tuesday . 1,634,405 shares were traded during mid-day trading, an increase of 15% from the previous session's volume of 1,417,938 shares.The stock last traded at $3.2230 and had previously closed at $3.06.

Analyst Ratings Changes

Several research firms have issued reports on MRVI. Wall Street Zen raised Maravai LifeSciences from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the company an "overweight" rating in a research note on Monday, December 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Maravai LifeSciences has an average rating of "Hold" and a consensus price target of $5.38.

Maravai LifeSciences Price Performance

The company has a market cap of $847.04 million, a P/E ratio of -3.66 and a beta of 0.43. The company has a fifty day moving average price of $3.17 and a two-hundred day moving average price of $3.34. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. The company had revenue of $49.87 million during the quarter, compared to analysts' expectations of $49.06 million. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%. On average, sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences

Several hedge funds have recently modified their holdings of the stock. Sprott Inc. bought a new position in Maravai LifeSciences during the third quarter worth about $29,000. Virtu Financial LLC bought a new position in Maravai LifeSciences during the fourth quarter worth about $34,000. Insigneo Advisory Services LLC bought a new position in Maravai LifeSciences during the fourth quarter worth about $34,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the third quarter worth about $31,000. Finally, Stifel Financial Corp bought a new position in Maravai LifeSciences during the fourth quarter worth about $36,000. Institutional investors own 50.25% of the company's stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.